For fiscal 2025, Knight has increased its financial guidance on revenues and adjusted EBITDA as a % of revenues. The Company expects to generate between $430 million to $440 million in revenues up from $410 to $420 million and adjusted EBITDA is expected to be between 13.5% to 14.5% of revenues up from 13%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics (KHTRF) Q3 Earnings Cheat Sheet
- Knight Therapeutics Secures US$100 Million Credit Facility to Boost Growth
- Knight Therapeutics announces approval, launch of MINJUVI in Argentina
- Knight Therapeutics announces relaunch of MYFEMBREE in Canada
- Knight Therapeutics announces relaunch of ORGOVYX in Canada